Back to Report Store Home

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease

  • Published: Apr-2018
  • Report Code: GBIHC471MR
  • Report Format: pdf

Description

Type 2 diabetes mellitus (T2DM) is a major metabolic disease and one of the leading causes of death worldwide. The prevalence is on the rise, alongside increases in obesity due to lifestyle changes in the 21st century. Type 2 diabetes is characterized by insulin resistance leading to dysregulation of glucose control and chronic hyperglycemia. This leads to several co-morbidities and complications, some of which are associated with damage to blood vessels as a result of elevated blood glucose levels. The disease is progressive: patients’ standard of living deteriorate over time and the symptoms worsen, meaning more complex treatment regimens are required over time. The complexity of the treatment means there is a high diversity of marketed products. In recent years new drug types have been great commercial successes and reached blockbuster status. This alongside the financial cost of type 2 diabetes to healthcare providers has led to significant investment in R&D on therapeutics in this area.

Scope

  • Requirement for new types of therapeutics to add to already complex treatment algorithms for severe T2DM

  • What are the most important etiological risk factors and pathophysiological processes implicated in T2DM?

  • What is the current treatment algorithm?

  • How effective are current therapies for these indications, and how does this impact prognosis? What are the side effects associated with these treatments?

  • The T2DM pipeline is dominated by G-protein-coupled receptors (GPCRs) and protein kinases

  • Which molecule types and molecular targets are most prominent in the T2DM pipeline?

  • Which first-in-class targets are most promising?

  • How does the level of first-in-class innovation change within different target classes?

  • How does first-in-class target diversity differ by stage of development and molecular target class?

  • The deals landscape is active and dominated by products that target GPCRS and protein kinases

  • Which molecular types/molecular target groups attract the highest deal values?

  • How has deal activity fluctuated over the past decade?

  • Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons To Buy

  • Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, and diagnosis and treatment options.

  • Identify leading products and key unmet needs within the market.

  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

  • Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for T2DM. Promising early-stage first-in-class targets are reviewed in greater detail.

  • Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards